PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Hanke, Nina; Frechen, Sebastian; Moj, Daniel; Britz, Hannah; Eissing, Thomas; Wendl, Thomas; Lehr, Thorsten

Hanke, Nina; Frechen, Sebastian; Moj, Daniel; Britz, Hannah; Eissing, Thomas; Wendl, Thomas; Lehr, Thorsten.

Affiliation

Hanke N; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Frechen S; Clinical Pharmacometrics, Bayer AG, Leverkusen, Germany.
Moj D; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Britz H; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Eissing T; Clinical Pharmacometrics, Bayer AG, Leverkusen, Germany.
Wendl T; Clinical Pharmacometrics, Bayer AG, Leverkusen, Germany.
Lehr T; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.

CPT Pharmacometrics Syst Pharmacol ; 7(10): 647-659, 2018 10.

Article in En | MEDLINE | ID: mdl-30091221

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rifampin / Midazolam / Alfentanil / Clarithromycin / Itraconazole / ATP Binding Cassette Transporter, Subfamily B, Member 1 / Digoxin / Cytochrome P-450 CYP3A / Models, Biological Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2018 Document type: Article Affiliation country: Alemania Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google